This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages without signing in

Trophoblastic tumours

Authoring team

Tumours arising from the trophoblast show a spectrum from benign hydatidiform mole to the frankly malignant choriocarcinoma.

Benign moles occur in 1 in 2500 to 1 in 5000 confinements in the UK, choriocarcinoma 1 in about 40,000. Five percent of moles are ultimately diagnosed as choriocarcinomas. One quarter arise from a normal or ectopic pregnancy.

Race, age, and a previous molar pregnancy are predisposing factors.

Pathologically, hydropic villi are commonly seen in benign lesions but are usually unidentifiable in choriocarcinoma. When present, metastases usually occur to the lower genital tract, lung, liver and brain.

Vaginal bleeding is a common early sign. All demonstrate raised beta-hCG which is used to monitor the course of the disease.

Treatment usually entails evacuation followed by chemotherapy and in highly metastatic disease, additionally, radiotherapy. Hysterectomy is usually advised in women over 40 years of age.

beta-hCG should be monitored for at least two years following initial treatment.

Tumours treated within 6 months of diagnosis enjoy a 95% cure rate.


Related pages

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.